TR199701013T1 - Nitrik oksit synthas'inin inhibitörleri olarak mercapto ve seleno türevleri. - Google Patents

Nitrik oksit synthas'inin inhibitörleri olarak mercapto ve seleno türevleri.

Info

Publication number
TR199701013T1
TR199701013T1 TR97/01013T TR9701013T TR199701013T1 TR 199701013 T1 TR199701013 T1 TR 199701013T1 TR 97/01013 T TR97/01013 T TR 97/01013T TR 9701013 T TR9701013 T TR 9701013T TR 199701013 T1 TR199701013 T1 TR 199701013T1
Authority
TR
Turkey
Prior art keywords
nitric oxide
mercapto
synthas
inhibitors
pharmaceutically acceptable
Prior art date
Application number
TR97/01013T
Other languages
English (en)
Inventor
J. Southan Garry
L. Salzman Andrew
Szabo Csaba
Original Assignee
Children's Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/410,312 external-priority patent/US5674907A/en
Application filed by Children's Hospital Medical Center filed Critical Children's Hospital Medical Center
Publication of TR199701013T1 publication Critical patent/TR199701013T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Bu bulus bir memelide nitrik oksit synthase'ini engellemek için, bir merkapto veya seleno türevi ile farmasötik olarak kabul edilebilir bir tasiyici içeren farmasötik olarak kabul edilebilir bir terkiple ilgilidir. Bulus ayrica, nitrik oksit synthase'i engellemek, nitrik oksit synthase'in tesvik edilebilir isoformunu seçici olarak engellemek ve nitrik oksit biyo sentezinin engellenmesinden bir yarar olan çesitli durumlarin tedavisi için bir yöntemle de ilgilidir. Yöntem, bir memeliye, ari haliyle veya farmasötik olarak kabul edilebilir bir tasiyici içinde bir merkapto veya seleno türevi uygulanmasi asamasini içerir.
TR97/01013T 1995-03-24 1996-03-22 Nitrik oksit synthas'inin inhibitörleri olarak mercapto ve seleno türevleri. TR199701013T1 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/410,312 US5674907A (en) 1995-03-24 1995-03-24 Mercapto derivatives as inhibitors of nitric oxide synthase
US08/545,952 US5929063A (en) 1995-03-24 1995-10-20 Mercapto and seleno derivatives as inhibitors of nitric oxide synthase

Publications (1)

Publication Number Publication Date
TR199701013T1 true TR199701013T1 (tr) 1998-02-21

Family

ID=27020952

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/01013T TR199701013T1 (tr) 1995-03-24 1996-03-22 Nitrik oksit synthas'inin inhibitörleri olarak mercapto ve seleno türevleri.

Country Status (17)

Country Link
US (2) US5929063A (tr)
EP (1) EP0814792B1 (tr)
JP (1) JPH11502847A (tr)
CN (1) CN1275594C (tr)
AT (1) ATE241347T1 (tr)
AU (1) AU695307B2 (tr)
BR (1) BR9607951A (tr)
CA (1) CA2214601C (tr)
CZ (1) CZ293497A3 (tr)
DE (1) DE69628416T2 (tr)
DK (1) DK0814792T3 (tr)
HU (1) HUP9801698A3 (tr)
MX (1) MX9707278A (tr)
NZ (1) NZ305228A (tr)
RU (1) RU2191575C2 (tr)
TR (1) TR199701013T1 (tr)
WO (1) WO1996030007A1 (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032575A1 (en) * 1996-03-05 1997-09-12 Children's Hospital Medical Center Mercapto derivatives as inhibitors of cyclooxygenases
WO1997045108A1 (en) * 1996-05-30 1997-12-04 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
JP2001507696A (ja) 1996-12-31 2001-06-12 アンチオキシダント ファーマシューティカルズ コーポレーション グルタチオンの医薬製剤およびその投与方法
FR2782642B1 (fr) * 1998-08-31 2001-12-07 Xavier Forceville Utilisation du selenium pour le traitement de patients atteints d'un syndrome de reponse inflammatoire systemique (sirs), et composition pour la mise en oeuvre du traitement
KR20010086383A (ko) 1998-09-08 2001-09-10 추후보정 유도성 일산화질소 합성효소 억제제를 사용한 골관절염치료법
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
DE102004063638A1 (de) * 2004-12-31 2006-07-13 Biosyn Arzneimittel Gmbh Selen-haltige Medikamente zur Prophylaxe oder Therapie von endothelialen Gefäßerkrankungen
EP1931328A4 (en) * 2005-08-16 2011-07-13 Discogen Llc METHOD FOR TREATING A GREENER SUBJECT WITH DEGENERATIVE DISCOPATHY USING AN INHIBITOR OF NITRIC OXIDE SYNTHASE
TW200744658A (en) * 2005-10-12 2007-12-16 Pentapharm Ag Topical composition for use as a skin lightener
WO2008128189A1 (en) 2007-04-13 2008-10-23 The Penn State Research Foundation Anti-cancer compositions and methods
US8003633B1 (en) 2008-04-14 2011-08-23 The Penn State Research Foundation Anti-cancer compositions and methods
CN114057619B (zh) * 2020-07-31 2024-03-22 深圳福山生物科技有限公司 有机硒化合物及其治疗用途
CN115785573B (zh) * 2022-12-02 2024-05-17 福建奥翔体育塑胶科技股份有限公司 一种持久抗菌型epdm颗粒及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1400319A (en) * 1972-04-20 1975-07-16 Smith Kline French Lab Pharmaceutical compositions
US5246971A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
ATE191847T1 (de) * 1991-12-16 2000-05-15 Univ Washington Verwendung von aminoguamidin zur herstellung eines arzneimittels zur unterdrückung der stickoxidbildung
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
IL107771A0 (en) * 1992-11-27 1994-02-27 Wellcome Found Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation

Also Published As

Publication number Publication date
CZ293497A3 (cs) 1998-02-18
EP0814792B1 (en) 2003-05-28
CN1275594C (zh) 2006-09-20
DE69628416D1 (de) 2003-07-03
JPH11502847A (ja) 1999-03-09
AU5319196A (en) 1996-10-16
US5985917A (en) 1999-11-16
US5929063A (en) 1999-07-27
AU695307B2 (en) 1998-08-13
CA2214601A1 (en) 1996-10-03
HUP9801698A3 (en) 2000-07-28
DE69628416T2 (de) 2004-05-06
CA2214601C (en) 2001-09-25
EP0814792A1 (en) 1998-01-07
BR9607951A (pt) 1999-06-01
MX9707278A (es) 1998-06-30
CN1181700A (zh) 1998-05-13
DK0814792T3 (da) 2003-09-29
NZ305228A (en) 1999-01-28
ATE241347T1 (de) 2003-06-15
RU2191575C2 (ru) 2002-10-27
HUP9801698A2 (hu) 1998-11-30
WO1996030007A1 (en) 1996-10-03

Similar Documents

Publication Publication Date Title
TR199701013T1 (tr) Nitrik oksit synthas'inin inhibitörleri olarak mercapto ve seleno türevleri.
HUP0203939A2 (hu) Gyógyhatású vegyületek és ezeket tartalmazó készítmények és alkalmazásuk
NO960534D0 (no) Amidinderivater med nitrogenoksydsynteseaktiviteter
ES2173185T3 (es) Empleo de derivados de tetrahidropteridina como inhibidores de la no-sintasa.
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
TR200200082T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
DE69020573T3 (de) Verfahren zur wachstumshemmung von stammzellen.
IL126674A0 (en) Urea derivatives as inhibitors of impdh enzyme and pharmaceutical compositions containing the same
TR199801168T2 (tr) Interleukin-1 beta dönüstürücü enzim inhibitörleri.
BR9811099A (pt) Inibidores de urocinase
UA35589C2 (uk) ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
AU1929199A (en) Methods for the recovery and measurement of troponin complexes
DK1053239T3 (da) Gluccocorticoid-selektive, anti-inflammatoriske midler
FI943728A0 (fi) Enkefalinaasin ja ACE:n inhibiittoreina käyttökelpoisia uusia aminoasetyylimerkaptojohdannaisia
ATE423562T1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
TR200002345T2 (tr) Glukokortikoit seçiçi antienflamatuar ajanlar
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
AU2209500A (en) Inhibitors of alpha4beta1 mediated cell adhesion
DE3162004D1 (en) Metal chelates of 1,4-bis(substituted-amino)-5,8-dihydroxy-anthraquinones
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
EA200000165A1 (ru) Разветвленные алкоксизамещенные-2-аминопиридины в качестве ингибиторов nos
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
BG103722A (en) Penylxanthine esters and amides
MX9701776A (es) Uso de factores de crecimiento similares a insulina i y ii para la inhibicion de la respuesta inflamatoria.
ATE228980T1 (de) Verwendung von alkoholen als additive für putze und/oder mörtel